Stay updated on Nivolumab Combo for Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo for Uveal Melanoma Clinical Trial page.

Latest updates to the Nivolumab Combo for Uveal Melanoma Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe clinical trial record for nivolumab plus ipilimumab in previously untreated metastatic uveal melanoma is now displayed, including study details, eligibility criteria, locations, and outcome measures.SummaryDifference50%

- Check16 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA site-wide banner announces NIH website updates and a terminology transition from “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe study page now renders a 403 Forbidden error, replacing the previous study record content with an error screen. As a result, the trial details, locations, and related information are no longer accessible on the page.SummaryDifference18%

Stay in the know with updates to Nivolumab Combo for Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo for Uveal Melanoma Clinical Trial page.